This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by RIIS, B. J. Articles by JACOBSON, J. Search for Related Content PubMed PubMed Citation Articles by RIIS, B. J. Articles by JACOBSON, J.

Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists?

Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen Glostrup, Denmark
the Department of Obstetrics and Gynecology, Södertälje Hospital (J.J.) Södertälje, Sweden

Address all correspondence and requests for reprints to: Bente Juel Riis, Department of Clinical Chemistry, Glostrup Hospital, DKH 2600 Glostrup, Denmark.

Recent studies have shown that treatment with the LHRH agonist nafarelin gives symptomatic and objective relief to women with endometriosis. Such a treatment, however, results in increased bone turnover and loss of bone mass. In the present study 17 women with endometriosis were treated with 400 mg nafarelin combined with 1.2 mg norethisterone (NET) for 6 months, followed by 6 months with only 1.2 mg NET. The data were compared to data from a previously published study of 9 women treated for 6 months with 400 mg nafarelin alone, followed by 6 months without treatment.

In the group treated with nafarelin plus NET the biochemical parameter of bone resorption (fasting urinary hydroxyproline) remained virtually unchanged, compared to a highly significant increase in the nafarelin-treated group. Estimates of bone formation (serum alkaline phosphatase and plasma bone Gla protein) increased in the nafarelin plus NET group, but to only a minor extent compared to those in the nafarelin group. In addition, bone mineral in the forearm, the spine, and the total skeleton remained virtually unchanged in the group treated with nafarelin plus NET, compared to the bone loss of 2-6%/6 months in the nafarelin group. We conclude that addition of NET to nafarelin treatment of endometriosis seems to have a bone-sparing effect.

Received June 20, 1989.

This article has been cited by other articles:

				A. E Lemus, J. Enriquez, A. Hernandez, R. Santillan, and G. Perez-Palacios Bioconversion of norethisterone, a progesterone receptor agonist into estrogen receptor agonists in osteoblastic cells J. Endocrinol., February 1, 2009; 200(2): 199 - 206. [Abstract] [Full Text] [PDF]

				J. Enriquez, A. E. Lemus, J. Chimal-Monroy, H. Arzate, G. A Garcia, B. Herrero, F. Larrea, and G. Perez-Palacios The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites J. Endocrinol., June 1, 2007; 193(3): 493 - 504. [Abstract] [Full Text] [PDF]

				H. Fernandez, C. Lucas, B. Hedon, J.L. Meyer, J.M. Mayenga, and C. Roux One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial Hum. Reprod., June 1, 2004; 19(6): 1465 - 1471. [Abstract] [Full Text] [PDF]

				J. H. Tobias, S. Clarke, K. Mitchell, S. Robins, H. Amer, and W. D. Fraser Analysis of the Contribution of Dydrogesterone to Bone Turnover Changes in Postmenopausal Women Commencing Hormone Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1194 - 1198. [Abstract] [Full Text]

				J. E. Compston Sex Steroids and Bone Physiol Rev, January 1, 2001; 81(1): 419 - 447. [Abstract] [Full Text] [PDF]

				K. K. Miller and A. Klibanski Amenorrheic Bone Loss J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1775 - 1783. [Full Text]

				J. S. Finkelstein, A. Klibanski, A. L. Arnold, T. L. Toth, M. D. Hornstein, and R. M. Neer Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone-(1-34): A Randomized Controlled Trial JAMA, September 23, 1998; 280(12): 1067 - 1073. [Abstract] [Full Text] [PDF]

				E. A. Amama, M. Taga, and H. Minaguchi The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 333 - 338. [Abstract] [Full Text]

				J. S. Finkelstein, A. Klibanski, E. H. Schaefer, M. D. Hornstein, I. Schiff, and R. M. Neer Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency N. Engl. J. Med., December 15, 1994; 331(24): 1618 - 1623. [Abstract] [Full Text]

				G. E.-H. Fuleihan, E. M. Brown, K. Curtis, M. J. Berger, B. M. Berger, R. Gleason, and M. S. LeBoff Effect of Sequential and Daily Continuous Hormone Replacement Therapy on Indexes of Mineral Metabolism Arch Intern Med, September 1, 1992; 152(9): 1904 - 1909. [Abstract] [PDF]